(Q40137119)

17 September 2017

1 reference

title

Chemotherapy of non-small cell lung cancer: a reappraisal and a look to the future (English)

1 reference

17 September 2017

1 reference

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

24 September 2023

author name string

M. T. Bakowski

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6311415

24 September 2023

J. C. Crouch

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6311415

24 September 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=6311415

24 September 2023

publication date

1 September 1983

1 reference

full work available at URL

17 September 2017

https://api.elsevier.com/content/article/PII:0305737283900300?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

https://api.elsevier.com/content/article/PII:0305737283900300?httpAccept=text/plain

24 September 2023

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

24 September 2023

published in

Cancer Treatment Reviews

1 reference

17 September 2017

volume

10

1 reference

17 September 2017

issue

3

1 reference

17 September 2017

page(s)

159-172

1 reference

Therapy of advanced squamous carcinoma of the lung: cyclophosphamide vesus "COMB".

17 September 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Chemotherapy of lung cancer: the experience of the National Cancer Institute of Milan

24 September 2023

3

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

5-Fluorouracil (NSC-19893) compared to cyclophosphamide (NSC-26271) in bronchogenic carcinoma: results of a clinical study

24 September 2023

7

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Phase II evaluation of chlorozotocin in patients with non-small cell carcinoma of the lung

24 September 2023

8

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung

24 September 2023

10

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC)

24 September 2023

12

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma.

24 September 2023

13

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Phase II study of chlorozotocin in non-small cell carcinoma of the lung

24 September 2023

14

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Adriamycin in advanced bronchogenic carcinoma

24 September 2023

15

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Ifosfamide in the treatment of extensive non-oat cell carcinoma of the lung

24 September 2023

17

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Phase II evaluation of triazinate in patients with metastatic lung cancer

24 September 2023

18

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Phase II evaluation of chlorozotocin in advanced bronchogenic carcinoma

24 September 2023

19

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Phase II evaluation of PALA in patients with metastatic lung cancer

24 September 2023

20

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Single-agent and combination chemotherapy for extensive non-small cell carcinomas of the lung

24 September 2023

22

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Hexamethylmelamine (NSC-13875) in the treatment of primary cancer of the lung with metastasis

24 September 2023

24

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Comparison of treatment policies in inoperable bronchial carcinoma

24 September 2023

25

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

ICRF-159 versus polychemotherapy in non-small cell lung cancer

24 September 2023

27

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Phase II evaluation of maytansine in patients with metastatic lung cancer

24 September 2023

28

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Evaluation of an intermittent schedule of mitolactol in advanced non-small cell lung cancer

24 September 2023

29

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung

24 September 2023

30

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Platinum-based polychemotherapy versus dianhydrogalactitol in advanced non-small cell lung cancer

24 September 2023

31

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Phase II study of high-dose methotrexate in the treatment of patients with non-small cell carcinoma of the lung: an Eastern Cooperative Oncology Group study

24 September 2023

35

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Vindesine: an effective agent in the treatment of non-small cell lung cancer

24 September 2023

36

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Clinical trial of rubidazone in advanced squamous cell carcinoma of the lung and adenocarcinoma of the large intestine

24 September 2023

37

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Phase II evaluation of pyrazofurin in patients with carcinoma of the lung

24 September 2023

38

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Phase II evaluation of vindesine in patients with non-small cell carcinoma of the lung

24 September 2023

39

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Phase II evaluation of bleomycin.A Southwest Oncology Group study

24 September 2023

40

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Single-dose ifosfamide: efficacy studies in non-small cell lung cancer

24 September 2023

41

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea, NSC-79037) in the treatment of cancer. Phase II study

24 September 2023

42

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

CCNU and bleomycin in the treatment of cancer: A southwest oncology group study

24 September 2023

43

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Results of a clinical trial with intermittent doses of adriamycin in lung cancer.

24 September 2023

44

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Phase II studies of methyl glyoxal bis-guanylhydrazone (NSC 32946) in carcinoma of the colon and lung

24 September 2023

45

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Adriamycin in the treatment of far-advanced lung cancer

24 September 2023

47

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Treatment of inoperable carcinoma of bronchus

24 September 2023

48

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

A randomized prospective study of vindesine versus doxorubicin and cyclophosphamide in the treatment of epidermoid lung cancer

24 September 2023

49

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Vindesine (VDS) monochemotherapy for non-small cell lung cancer: a report of 45 cases

24 September 2023

50

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Ifosfamide: a weekly dose fractionated schedule in bronchogenic carcinoma

24 September 2023

51

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Vindesine in the treatment of small cell and non-small cell bronchogenic carcinoma: preliminary results

24 September 2023

52

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Phase II evaluation of AMSA in patients with metastatic lung cancer

24 September 2023

53

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B

24 September 2023

54

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Phase II evaluation of adriamycin in human neoplasia

24 September 2023

55

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Vindesine in the treatment of squamous cell carcinoma, adenocarcinoma, and large cell carcinoma of the lung

24 September 2023

56

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Chemotherapy for inoperable, non-small cell bronchogenic carcinoma: EST 2575, generation II

24 September 2023

59

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

VM26 (NSC-122819): A clinical study in advanced cancer of the lung and ovary

24 September 2023

62

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Mitomycin C in advanced adenocarcinoma and large cell carcinoma of the lung

24 September 2023

63

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Phase II study of AMSA in lung cancer

24 September 2023

64

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Methotrexate compared with placebo in lung cancer

24 September 2023

67

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Methotrexate in the chemotherapy of lung cancer

24 September 2023

68

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Trial of 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) in Advanced Bronchogenic Carcinoma

24 September 2023

70

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Hexamethylmelamine in inoperable bronchogenic carcinoma

24 September 2023

71

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Effect of CCNU (NSC-79037) on bronchogenic carcinoma

24 September 2023

72

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Intermittent high-dose cyclophosphamide with and without prednisolone: a study of the relationships between toxicity, response and survival in metastatic lung cancer

24 September 2023

73

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Oral high-dose methotrexate with citrovorum factor rescue in metastatic squamous cell carcinoma of the lung

24 September 2023

74

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Evaluation of methotrexate in the treatment of bronchogenic carcinoma

24 September 2023

75

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

Efficacy study of intensive cis-platin therapy in advanced non-small cell bronchogenic carcinoma

24 September 2023

77

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

A Phase III Study in Lung Carcinoma Comparing Hexamethylmelamine (NSC 13875) to Dibromodulcitol (NSC 104800)

24 September 2023

79

1 reference

https://api.crossref.org/works/10.1016/0305-7372(83)90030-0

24 September 2023

Identifiers

1 reference

17 September 2017

1 reference